336681
Increased Substance Use among Russian Women with HIV and Hepatitis C Co-Infection: Implications for Assessment and Intervention
Methods: HIV-infected women (N=247; M age = 30.0) receiving medical care in St. Petersburg, Russia, completed an audio computer-assisted self-interview (ACASI) that assessed substance use, the co-occurrence of substance use and sexual behaviors, and measures of problematic substance use (e.g., AUDIT). Medical chart review established HCV diagnosis. Logistic and linear regression analyses compared HIV/HCV co-infected participants’ patterns of substance use to those only infected with HIV.
Results: More than half of the sample (57.1%) was HIV/HCV co-infected. HIV/HCV co-infected participants reported more frequent binge drinking (β=.15, p=.05), problem drinking based on the AUDIT (β=.15, p=.01), greater substance use problems based on the DAST (β=.19, p=.03), and increased likelihood of unprotected sex when drinking at the last sexual encounter (AOR=2.2, p=.007).
Conclusions: HIV/HCV co-infection was prevalent among this sample and was associated with increased substance use and the co-occurrence of substance use and sexual risk behaviors. Findings highlight the need for ongoing substance use and HIV risk behavior assessment and development and evaluation of interventions targeting both substance use and HIV risk among HIV/HCV co-infected Russian women.
Learning Areas:
Public health or related researchSocial and behavioral sciences
Learning Objectives:
Evaluate differential patterns of substance use by HIV/HCV co-infected Russian women
Keyword(s): HIV/AIDS, Hepatitis C
Qualified on the content I am responsible for because: Dr. DiClemente is an expert in the field of HIV/AIDS prevention research. He has his PhD and over 10+ years of experience within the field of public health and behavioral research.
Any relevant financial relationships? No
I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.